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INTRODUCTION
Clinical trials in Europe
The evolution of clinical trials passed through 
a very long and strewn with many difficulties times. 
From the first study, performed on a bean in bibli-
cal times, to the first randomized trial. For all that 
time the history of clinical trials goes through a se-
ries of challenges - scientific, ethical and mostly reg-
ulatory (8).
Pharmacists are traditionally involved in clini-
cal trial research in a variety of ways, through differ-
ent activities: from providing medicine and keeping 
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PURPOSE: The aim of our research is to study the role and responsibilities of the hospital pharmacists in 
conducting clinical trials in Bulgaria.
MATERIAL AND METHODS: A special questionnaire was developed in the Faculty of Pharmacy, MU-
Sofia. A total number of 30 hospital pharmacies were contacted and included in the study. Three of them re-
fused to take part in the survey. The interview was via phone and included 4 questions (3 closed and 1 open). 
Mainly the head hospital pharmacy manager of the participating health institutions was interviewed. 
RESULTS: Analysis of the results shows that current practice in Bulgaria allowed hospital pharmacists to 
be involved in clinical trials but this case is not prevalent. The majority of the trials, conducted in our coun-
try that includes hospital pharmacies were with narcotic investigational products, which according to the 
specific local legislation can only be located at the site of the hospital pharmacy in a special metal shelf box. 
However there are lots of trials conducted without participation of hospital pharmacist/research pharma-
cist.
CONCLUSION: The participation of the hospital pharmacist can be extended – to help manage adverse 
events, monitor the effect of the drugs under the study and awareness for the drug-to-drug interactions. 
There are protocols where apart from the investigational product – there are non-drugs under the study, i.e. 
placed on the market which should be dispensed at the beginning of the trials during the washout period 
and again here is the place for the research pharmacist to control these non-investigational products. 
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record for drug accountability to taking part as co-
ordinators or principal investigators (11). Today, hos-
pital pharmacists are on the forefront of patient care 
(14). They have a significant impact on the patients’ 
health status, directly with value-added pharmacy 
services (12) and indirectly by connecting patients to 
pharmaceutical treatments (10) through the practice 
of Evidence Based Medicine (2) with existing treat-
ment or with participation in clinical trials (6). The 
work of clinical and hospital pharmacists includes 
philosophy of care, combined with a specific orien-
tation towards the patients to ensure optimal results 
from the ongoing pharmacotherapy (5).
The difference in responsibilities of the partic-
ipants in the agreements about the clinical trials is 
due to the fact that usually the party elaborating the 
agreement focuses its attention on the obligations of 
the other party – in this case the emphasis lays on the 
obligations of the principal investigator and the tri-
al site (4).
Currently the largest and the most commonly 
used international clinical trial register is the www.
clinicaltrials.gov (15). This is an easily accessible da-
tabase of ongoing clinical trials found on the Inter-
net. The database provides information about both 
patients and healthcare professionals on clinical tri-
als for a wide range of diseases and conditions (9). 
According to it, the results from the search about 
clinical trials conducted in Europe – up to 28 De-
cember 2013 are 43379 clinical studies and 11486 of 
these studies are still opened and recruiting patients. 
The research pharmacist concept 
Pharmacists can improve the quality of drug 
therapy by improving the organizational structures 
through which drug therapy is provided, specifically 
by creating medications use systems and by regular-
ly evaluating their performance (7). The clinical tri-
al team includes doctors, pharmacist (often called re-
search pharmacist), nurses, injectors, as well as other 
healthcare professionals (1). The research pharmacist 
is an appropriate, qualified individual (i.e. licensed/
registered) designed by the protocol to perform the 
day-to-day pharmacy activities and study product 
management including, but not limited to – the pro-
curement, storage, preparation, dispensing and final 
disposition of study products (3).
Advantages of having a hospital pharmacist 
involvement while conducting a clinical trial
 ❖ Better conditions for drug storage;
 ❖ The research pharmacist is responsible for 
proper drug dispensing and allocation;
 ❖ The research pharmacist is responsible for 
maintaining the logs related to the Investiga-
tional Product (IP).
MATERIAL AND METHODS
Using pseudo-randomization we selected a 
sample of 30 hospital pharmacies and the pharma-
cy managers were interviewed with a standardized 
questionnaire. Hospital pharmacists’ role and partic-
ipation in clinical trials were examined.
The aim of our research is to study the role and 
responsibilities of the hospital pharmacists in clini-
cal trials in Bulgaria. We contacted 30 hospital phar-
macies. Three of the pharmacy managers refused to 
participate and the rest (n=27) were contacted direct-
ly. The interview was via phone call and all of them 
were asked 4 questions – 3 of them closed-ended and 
1 open-ended. 
RESULTS
Among the 30 hospital pharmacy managers in-
cluded in our telephone research study, 27 respond-
ed, with an overall response rate of 90%.
The first question we asked the contacted phar-
macy managers at the hospital was:
 ❖ How many pharmacists work at the hospital 
pharmacy?
From the interviewed 27 managers of hospital 
pharmacies, two of them refused to answer the ques-
Fig. 1. Relationship in the research team
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tion, insisting that this information is confidential 
(Fig. 2).
The second question we asked was:
 ❖ Do you know if there are ongoing clinical trials 
in the hospital?
Sixteen out of 25 managers of hospital pharma-
cies confessed, that they knew that there were ongo-
ing clinical trials in their hospital (Fig. 3).
The third question we asked was:
 ❖ Are the hospital pharmacists/the hospital 
pharmacy involved in the Clinical Trial?
Unfortunately, only 6 of those 16 who admitted 
that there are ongoing clinical trials in the hospitals 
they work– were invlolved in those same trials, or at 
least in one of them (Fig. 4).
The fourth question we asked the interviewed 
pharmacists was asked only to those six, who an-
swered positively to question №3:
 ❖ What were the tasks and competences you 
have?
DISCUSSION
Clinical trials in Bulgaria
Nowadays the funding for the public hospitals 
in Bulgaria is insufficient (13) so taking part in clini-
cal trials could help the hospital to fill at least few of 
its financial gaps and improve the financial results. 
In spite of this, not every hospital has the opportuni-
ty to take part in a clinical trial. According to www.
clinicaltrials.gov, there are 959 ongoing clinical stud-
ies in Bulgaria as of December 2013. 233 studies from 
these (approximately one thousand) are still open for 
recruiting patients. 
According to the Bulgarian Law – involvement 
of a hospital pharmacy and a research pharmacist 
is obligatory only when the investigated product 
is a narcotic or consists a narcotic substance. In 
the contract between the hospital and the clinical 
research organization (CRO) is clearly stated that 
one of the obligations is the enrolment of the hospital 
pharmacy. Another point is when the protocol has 
blinded and unblinded team – usually a pharmacist 
is needed for the unblinded team, but in this case 
the role of the research pharmacist could also be 
taken by a doctor. Such a possibility leads to the 
Fig. 2. Number of pharmacists working in the hospital 
pharmacies we contacted.
Fig. 3. Number of hospital pharmacies managers aware 
that there are ongoing clinical trials in the hospital at the 
moment
Fig. 4. Involvement of hospital pharmacist/hospital phar-
macies in the clinical trial
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abovementioned results for the participation of 
hospital pharmacists in clinical trials in Bulgaria.
In hospital settings it is extremely important 
that proper medication is allocated to any patient 
in need at any time under appropriate form. On the 
other hand, drug use monitoring during clinical tri-
als is important to be done not only by physicians but 
also by a hospital and/or clinical pharmacist. Clinical 
research in humans is conducted in phases. Phase 1 
trials are the first studies to involve human subjects. 
These are small studies using healthy volunteers in 
order to evaluate the safe doses, the route of admin-
istration, pharmakokinetiks and establish some side 
effects. Phase 2 studies are related to safety and ef-
ficacy of a drug and evaluate how the drug affects 
the body of patients with the targeted disease. After 
the drug shows promise in early life – phase 3 tri-
als are conducted. These are very large studies whose 
patients may be national or international, depending 
on the trial. Phase 3 usually compares the new drug 
with the current standard of therapy in patients with 
the targeted disease. All these phases are suitable for 
involving pharmacists to ensure IP quality, study re-
sults (efficacy) and participants’ safety.
CONCLUSIONS
The majority of the clinical trials conducted in 
Bulgaria that involved hospital pharmacies were with 
IP – narcotic. This special requirement according to 
the Bulgarian law can be the only one reason to in-
clude the hospital pharmacy staff in clinical trials. 
Analysis of the results shows that current legislation 
and practice in Bulgaria allowed the hospital phar-
macist to be involved in clinical trials but this prac-
tice is not prevalent. There is no definitive require-
ment to include a pharmacist in the study team which 
has to be followed from the regulatory agency during 
clinical trial assessment and authorization. However 
there are lots of trials conducted without the partic-
ipation of hospital pharmacist/research pharmacist.
The participation of the hospital pharmacist can 
be extended – by helping for monitoring AE, moni-
tor the effect of the drugs under the study, monitor 
the drug-to-drug interactions, etc. There are many 
protocols where apart from the IP – there are medic-
inal products placed on the market, which should be 
dispensed at the beginning of the trials during the 
washout period and again here is the place for the 
research pharmacist to control these non-investiga-
tional products. 
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